ScreenerHero

SLS SELLAS Life Sciences Group, Inc.

NAS · US · Healthcare · Biotechnology · sellaslifesciences.com
11.31USD-0.26%Mkt Cap: 2.28B $P/E: —

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.28B USD
Enterprise Value2.15B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.86M USD
Revenue/Share—
Last Price11.31 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-113.40
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B16.63
EPS (TTM)-0.20
EPS (Forward)-0.10
52W Range
1.39068% of range15.88
52W High15.88 USD
52W Low1.390 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.90%
ROA-34.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.39M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-0.72%
Net Debt-137.61M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio18.83
Quick Ratio18.28
Book Value/Sh0.68 USD
Cash/Share0.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 8, 2019
Splits
Last Split1:50
Split DateNov 8, 2019
Analyst Consensus
Rating—
Target (Mean)32.50 USD
Upside (mean)+187.4%
Target Range30.00 USD – 35.00 USD
30.00+187.4% to mean35.00
# Analysts2
Ownership
Shares Out.201.95M
Float201.15M
Insiders0.92%
Institutions36.97%
Short Interest
Short Ratio7.6d
Short % Float29.37%
Short % Out.29.25%
Shares Short59.07M
Short (prev mo.)56.37M
Technical
SMA 5012.33 (-8.3%)
SMA 2007.875 (+43.6%)
Beta2.57
S&P 52W Chg16.45%
Avg Vol (30d)6.53M
Avg Vol (10d)4.72M
Technical Indicators
RSI (14)43.5
MACD-0.3020
MACD Signal-0.2174
MACD Hist.-0.0846
BB Upper13.93 USD
BB Middle12.08 USD
BB Lower10.23 USD
BB Width30.68%
ATR (14)0.8507 USD
Vol Ratio (20d)0.51x